Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Period	PE Ratio
2016-12-31	97.68
2017-12-31	94.49
2018-12-31	75.60
2019-12-31	51.75
2020-12-31	65.86
2021-12-31	36.07
2022-12-31	35.34
2023-12-31	37.63
2024-12-31	12.45
2025-12-31	47.25

	A	B	C	D
1	Symbol	Price	Change	Volume
2	EW	$86.94	+1.35%	1.30M
3
4
5

Edwards Lifesciences Corporation (EW) PE Ratio

PE Ratio Data

Get Edwards Lifesciences Corporation Data in Excel

More EW Financial Data